Recent studies have suggested that immunomodulator29 and anti-TNF exposure30 may in fact be associated with lower cancer risk, but it is uncertain as to whether this is indirectly a result of achieving inflammatory control and mucosal healing or a direct chemoprotective effect. This evidence concerns the gene TNF and cancer.